Search

Your search keyword '"Zeybek, Burak"' showing total 277 results

Search Constraints

Start Over You searched for: Author "Zeybek, Burak" Remove constraint Author: "Zeybek, Burak"
277 results on '"Zeybek, Burak"'

Search Results

1. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

2. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

3. Integrated mutational landscape analysis of uterine leiomyosarcomas

4. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo

6. Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma

7. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

8. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma

9. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib

10. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers

11. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitor

21. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

28. Alterations in Pre/Post Oxygenator Flows Due to Fibrin Deposition in the CardioHelp System—A Case Report

31. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

35. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

36. In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma

38. Financial toxicity in patients with gynecologic malignancies

39. Charlson Comorbidity Index as a predictor of postoperative complication in octogenarians and nonagenarians with stage I endometrioid endometrial cancer: a single-institution retrospective review

40. Abstract 911:In vitroandin vivoactivity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma

45. Financial toxicity in patients with gynecologic malignancies: a cross sectional study

46. Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study

47. Abstract 5341: Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma

Catalog

Books, media, physical & digital resources